arrow
M

Michal Lotem

hebrew university of jerusalem
H指数:40
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006

pembrolizumab治疗晚期黑色素瘤患者后ipilimumab或BRAF ± MEK抑制的抗肿瘤活性: 来自KEYNOTE-006的分析

2022-02-015
OAAI
Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma

联合展示和免疫原性分析揭示了黑色素瘤中反复出现的RAS.Q61K新抗原

2021-10-1515
OA
TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment

PDAC中的TP53错义突变与增强的纤维化和免疫抑制微环境有关

2021-06-0469
OA
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR
2021-05-0124
OAAI